FINHUB Insights

VRTX · Q2 FY26 · Apr 1 – Jun 30, 2026

Vertex Pharmaceuticals Q2 FY26: where the revenue came from and where it went

Vertex Pharmaceuticals Q2 FY26: revenue $3.3B (+12% year over year). Net profit $1.1B. Largest cohort Trikaftakaftrio $2.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
Aug 4, 2026 10-Q
Sankey diagram of Vertex Pharmaceuticals's income statement for Q2 FY26: revenue of $3.33 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.33B +12% year over year
Gross profit$2.85B 85% margin
Operating profit$1.25B 37% margin
Net profit$1.10B 33% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 3.33 100% +12%
Trikaftakaftrio 2.50 75% −2%
Alyftrek 0.57 17% +266%
Manufactured product other 0.14 4% −29%
Casgevy 0.08 2% +151%
Journavx 0.05 1% +313%
Cost of revenue−0.4915%
Gross profit2.8585% margin−1pp
SG&A−0.5817%+3pp
Other−1.0230%+0pp
Operating profit1.2537% margin−1pp
Tax−0.29
Net profit1.1033%−2pp
Filing on EDGAR More quarters of VRTX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.